Cardiovascular (CV) RiskNCT07869069
Advancing Health Equity and Preventive Cardiovascular Care in Indigenous and Remote Communities: a Mobile Healthcare Unit
A study testing Cardiovascular risk screening and Follow-up of cardiovascular risk factors in people with Cardiovascular (CV) Risk and Metabolic Health, run by Laval University at 1 site in Canada.
Trial summary
Indigenous people living in Canada face significant healthcare inequities, particularly in basic, primary, and secondary prevention, leading to higher rates of cardiovascular disease and mortality. Read more about this study
- Who is it for?
- Ages 35 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular (CV) Risk, Metabolic Health, Primary Prevention
- What is being tested?
- Cardiovascular risk screening and Follow-up of cardiovascular risk factors
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteCanada
- Study dates
- 11 Feb 2026to 31 Mar 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- BMI > 27 kg/m^2
Who cannot join
- Being pregnant;
- Known heart condition
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
IUCPQ-ULaval
Québec, Quebec
Coordinator, 1-418-656-8711, santeinclusive@criucpq.ulaval.ca
About this study
Indigenous people living in Canada face significant healthcare inequities, particularly in basic, primary, and secondary prevention, leading to higher rates of cardiovascular disease and mortality. This program aims to develop a comprehensive understanding of the contextual and individual determinants influencing Indigenous health, and to address health disparities by using tailored community-led participatory research and care initiatives. The investigator and research team use a Mobile Healthcare Unit travelling to Indigenous communities, providing customized, impactful, and sustainable preventive care that adapts dynamically to the evolving needs of each community. The initiative places a strong emphasis on equity and inclusivity, aiming to generate original data in Indigenous and remote underrepresented/underserved populations. This proposal will improve opportunities of identifying facilitators and barriers to preventive care in Indigenous and remote communities. This focus is vital for reducing health disparities and aligns with the Truth and Reconciliation Calls to Action. To maximize knowledge mobilization and ensure culturally appropriate initiatives align with community needs and priorities, this research program collaborates with the Indigenous University Hub at Laval University, local community members and leaders, and Indigenous peoples with lived experience. Existing national and international collaborations with Indigenous communities further enhance the initiative's potential impact and foster knowledge mobilization on a global scale. The ultimate goal is to empower Indigenous peoples and communities to advocate for systemic changes to fight inequities in healthcare in accordance with appropriated truth and reconciliation efforts.
Read the detailed description
This pilot study will take place in the Mobile Healthcare Unit (motorized vehicle) that will travel to 10 Indigenous and/or remote communities.This study aims at collecting cardiovascular (CV) data and delivering culturally appropriate research and care in underserved/underrepresented populations. Collaborating members of the communities visited will be involve in the mobile care service and will assist as translators. Recruitment and data collection will be carried out by the investigator at the IUCPQ-ULaval in collaboration with the participating communities. This study was co-designed and accepted by health departments and participating communities. Each participant will undergo a comprehensive assessment of CV risk factors and CV conditions at the beginning of the study. This assessment will be standardized and will include the following elements:
- Clinical examination including anthropometric measurements;
- Auscultation by a cardiologist with a digital stethoscope;
- Translated and validated questionnaires on demographics and medical history;
- Pregnancy and reproductive health questionnaires;
- Blood pressure, assessed by oscillometry;
- Peripheral artery disease assessment;
- Cardiometabolic blood markers (NT-proBNP, HbA1C, hs-CRP, CBC, lipids, etc.)
- Arrythmia and atrial fibrillation, assessed by electrocardiogram;
- Anthropometric indices and body fat distribution by elastography;
- Maximal stress test on a treadmill;
- Questionnaire on participant satisfaction and areas of improvement in health equity.
- Being tested
- Cardiovascular risk screening, Follow-up of cardiovascular risk factors
- Keywords
- Cardiovascular Disease, Cardiovascular-Kidnay-Metabolic Health, Community-Driven AND Culturally Safe Care and Research, Diabetes, Health Equity and Inclusivity, Indigenous Health, Mobile Healthcare Unit, Preventive Care, Social Determinants of Health, Women's Health
- Medical subject headings
- Cardiovascular Diseases, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiovascular risk screeningOther
Extensive cardiovascular risk screening offered locally in underserved/ underrepresented communities (see Study Description for more details)
Follow-up of cardiovascular risk factorsOther
Measure changes in cardiovascular risk factors among participants who took place in the screening phase.
| Study group | Role | What they receive |
|---|---|---|
| Preventive care | Other | Not described Receives: Other: Cardiovascular risk screening; Other: Follow-up of cardiovascular risk factors |
What is being measured
The primary outcome is the main question the study is designed to answer.
Height in meters
Measured using a stadiometer
Measured: Once, at baseline.
Weight in kilograms
Measured using an electronic body scale
Measured: At baseline and at 1 year
Body mass index in kg/(m^2)
BMI will be calculated by dividing the weight in kilograms by the square of the height in meters
Measured: At baseline and at 1 year
Waist circumference in centimeters
Waist circumference will be measured using an ergonomic circumference measuring tape
Measured: At baseline and at 1 year
Blood pressure
In mm Hg, using a digital blood pressure device
Measured: At baseline and at one-year follow-up
Lipid profile
Assessment of hypercholesterolemia (LDL-C, HDL-C, triglycerides, non-HDL-C in mmol/L) and apoB levels in g/L.
Measured: At baseline and at one-year follow-up
Physical activity measure
Using the International Physical Activity Questionnaire (IPAQ)
Measured: At baseline and at one-year follow-up
Glycated hemoglobin (HbA1c)
Blood test, expressed as %
Measured: At baseline and at one-year follow-up
Dietary habits
Frequency of intake per month of fruits, vegetables, whole grains, lean proteins, saturated fats and added sugars, using the Canadian Food Intake Screener.
Measured: At baseline and at one-year follow-up
Smoking habits
Self-reported smoking habits as current smoker, former smoker or never smoked, as well as frequency of smoking
Measured: At baseline and at one-year follow-up
Framingham risk score
Estimated 10-year cardiovascular risk, expressed as a percentage (%)
Measured: At baseline and at one-year follow-up
Secondary outcomes (1)
Participant feedback on intervention
Questionnaire on participant satisfaction and areas of improvement in health equity.
Measured: At baseline and at one-year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2026
- Study start11 Feb 2026
- Primary completion31 Mar 2029 (estimated)
- Study completion31 Mar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular (CV) RiskStudies of the same condition, open and under way.
- More trials run by Laval UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Laval University
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Responsible party
- Principal investigator, Marie-Eve Piché, Laval University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07869069
- Sponsor's protocol ID
- 543568
- Status last verified
- Oct 2026
- First submitted
- 24 Feb 2026
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: According to OCAP(TM) principles, each community owns their data, controls its dissemination, and decides when and what research is in the best interests of their specific community.
Publications
Lajeunesse-Trempe F, Boit MK, Kaduka LU, De Lucia-Rolfe E, Baass A, Paquette M, Piche ME, Tchernof A, Christensen DL. Validation of the Fatty Liver Index for identifying non-alcoholic fatty liver disease in a Kenyan population. Trop Med Int Health. 2023 Oct;28(10):830-838. doi: 10.1111/tmi.13927. Epub 2023 Aug 31.
PubMed 37650501Leveille N, Provost H, Keutcha Kamani C, Chen M, Deghan Manshadi S, Ades M, Shanahan K, Nauche B, Drudi LM. Exploring Prognostic Implications of Race and Ethnicity in Patients With Peripheral Arterial Disease. J Surg Res. 2024 Oct;302:739-754. doi: 10.1016/j.jss.2024.07.120. Epub 2024 Aug 30.
PubMed 39216457Lajeunesse-Trempe F, Piche ME, Kaduka L, Lopez Y Taylor JR, Sagastume RC. Moving from helicopter research to proximity research and capacity building. Trends Endocrinol Metab. 2025 Mar;36(3):193-195. doi: 10.1016/j.tem.2024.08.011. Epub 2024 Oct 1.
PubMed 39358160Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Apr 30;73(16):2106-2116. doi: 10.1016/j.jacc.2018.12.092.
PubMed 31023435Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
PubMed 33882682Norris CM, Yip CYY, Nerenberg KA, Clavel MA, Pacheco C, Foulds HJA, Hardy M, Gonsalves CA, Jaffer S, Parry M, Colella TJF, Dhukai A, Grewal J, Price JAD, Levinsson ALE, Hart D, Harvey PJ, Van Spall HGC, Sarfi H, Sedlak TL, Ahmed SB, Baer C, Coutinho T, Edwards JD, Green CR, Kirkham AA, Srivaratharajah K, Dumanski S, Keeping-Burke L, Lappa N, Reid RD, Robert H, Smith G, Martin-Rhee M, Mulvagh SL. State of the Science in Women's Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender. J Am Heart Assoc. 2020 Feb 18;9(4):e015634. doi: 10.1161/JAHA.119.015634. Epub 2020 Feb 17. No abstract available.
PubMed 32063119Reading J. Confronting the Growing Crisis of Cardiovascular Disease and Heart Health Among Aboriginal Peoples in Canada. Can J Cardiol. 2015 Sep;31(9):1077-80. doi: 10.1016/j.cjca.2015.06.012. Epub 2015 Jun 21.
PubMed 26321431Piche ME, Tchernof A, Despres JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020 May 22;126(11):1477-1500. doi: 10.1161/CIRCRESAHA.120.316101. Epub 2020 May 21.
PubMed 32437302Aziz H, Marchand M, Pop C, King A, Anand SS, Arbour L, Atzema C, Spaziano M, Merveille N, Filimon S, Poirier P, Huynh T. A Call to Action: Optimizing Indigenous Cardiovascular Health in Canada. Can J Cardiol. 2022 Oct;38(10):1584-1587. doi: 10.1016/j.cjca.2022.06.011. Epub 2022 Jun 16. No abstract available.
PubMed 35718241Lajeunesse-Trempe F, Piche ME, Poirier P, Tchernof A, Ayotte P. Adiposity Phenotypes and Associated Cardiometabolic Risk Profile in the Inuit Population of Nunavik. Nutrients. 2024 Mar 2;16(5):725. doi: 10.3390/nu16050725.
PubMed 38474854Anand SS, Abonyi S, Arbour L, Balasubramanian K, Brook J, Castleden H, Chrisjohn V, Cornelius I, Davis AD, Desai D, de Souza RJ, Friedrich MG, Harris S, Irvine J, L'Hommecourt J, Littlechild R, Mayotte L, McIntosh S, Morrison J, Oster RT, Picard M; Pictou Landing First Nation; Poirier P, Schulze KM, Toth EL; Canadian Alliance for Healthy Hearts and Minds First Nations Research Group. Explaining the variability in cardiovascular risk factors among First Nations communities in Canada: a population-based study. Lancet Planet Health. 2019 Dec;3(12):e511-e520. doi: 10.1016/S2542-5196(19)30237-2.
PubMed 31868600
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Advancing Health Equity and Preventive Cardiovascular Care in Indigenous and Remote Communities: a Mobile Healthcare Unit
- ClinicalTrials.gov ID
- NCT07869069
- Acronym / sponsor ID
- 543568
- Keywords
- Cardiovascular Disease, Cardiovascular-Kidnay-Metabolic Health, Community-Driven AND Culturally Safe Care and Research, Diabetes, Health Equity and Inclusivity, Indigenous Health, Mobile Healthcare Unit, Preventive Care
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Laval UniversityUniversity, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR)
- Study start
- 11 Feb 2026 (actual)
- Primary completion
- 31 Mar 2029 (estimated)
- Study completion
- 31 Mar 2030 (estimated)
- First posted
- 9 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Indigenous people living in Canada face significant healthcare inequities, particularly in basic, primary, and secondary prevention, leading to higher rates of cardiovascular disease and mortality. This program aims to develop a comprehensive understanding of the contextual and individual determinants influencing Indigenous health, and to address health disparities by using tailored community-led participatory research and care initiatives. The investigator and research team use a Mobile Healthcare Unit travelling to Indigenous communities, providing customized, impactful, and sustainable preventive care that adapts dynamically to the evolving needs of each community. The initiative places a strong emphasis on equity and inclusivity, aiming to generate original data in Indigenous and remote underrepresented/underserved populations. This proposal will improve opportunities of identifying facilitators and barriers to preventive care in Indigenous and remote communities. This focus is vital for reducing health disparities and aligns with the Truth and Reconciliation Calls to Action. To maximize knowledge mobilization and ensure culturally appropriate initiatives align with community needs and priorities, this research program collaborates with the Indigenous University Hub at Laval University, local community members and leaders, and Indigenous peoples with lived experience. Existing national and international collaborations with Indigenous communities further enhance the initiative's potential impact and foster knowledge mobilization on a global scale. The ultimate goal is to empower Indigenous peoples and communities to advocate for systemic changes to fight inequities in healthcare in accordance with appropriated truth and reconciliation efforts.
Detailed description
This pilot study will take place in the Mobile Healthcare Unit (motorized vehicle) that will travel to 10 Indigenous and/or remote communities.This study aims at collecting cardiovascular (CV) data and delivering culturally appropriate research and care in underserved/underrepresented populations. Collaborating members of the communities visited will be involve in the mobile care service and will assist as translators. Recruitment and data collection will be carried out by the investigator at the IUCPQ-ULaval in collaboration with the participating communities. This study was co-designed and accepted by health departments and participating communities. Each participant will undergo a comprehensive assessment of CV risk factors and CV conditions at the beginning of the study. This assessment will be standardized and will include the following elements:
- Clinical examination including anthropometric measurements;
- Auscultation by a cardiologist with a digital stethoscope;
- Translated and validated questionnaires on demographics and medical history;
- Pregnancy and reproductive health questionnaires;
- Blood pressure, assessed by oscillometry;
- Peripheral artery disease assessment;
- Cardiometabolic blood markers (NT-proBNP, HbA1C, hs-CRP, CBC, lipids, etc.)
- Arrythmia and atrial fibrillation, assessed by electrocardiogram;
- Anthropometric indices and body fat distribution by elastography;
- Maximal stress test on a treadmill;
- Questionnaire on participant satisfaction and areas of improvement in health equity.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Preventive care | Other | Other: Cardiovascular risk screening, Other: Follow-up of cardiovascular risk factors |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- BMI > 27 kg/m^2
Key exclusion criteria (2 listed)
- Being pregnant;
- Known heart condition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cardiovascular risk screeningExtensive cardiovascular risk screening offered locally in underserved/ underrepresented communities (see Study Description for more details) | Other | Preventive care |
| Follow-up of cardiovascular risk factorsMeasure changes in cardiovascular risk factors among participants who took place in the screening phase. | Other | Preventive care |
Primary outcome
Height in meters
Time frame: Once, at baseline.
Measured using a stadiometer
Weight in kilograms
Time frame: At baseline and at 1 year
Measured using an electronic body scale
Body mass index in kg/(m^2)
Time frame: At baseline and at 1 year
BMI will be calculated by dividing the weight in kilograms by the square of the height in meters
Waist circumference in centimeters
Time frame: At baseline and at 1 year
Waist circumference will be measured using an ergonomic circumference measuring tape
Blood pressure
Time frame: At baseline and at one-year follow-up
In mm Hg, using a digital blood pressure device
Lipid profile
Time frame: At baseline and at one-year follow-up
Assessment of hypercholesterolemia (LDL-C, HDL-C, triglycerides, non-HDL-C in mmol/L) and apoB levels in g/L.
Physical activity measure
Time frame: At baseline and at one-year follow-up
Using the International Physical Activity Questionnaire (IPAQ)
Glycated hemoglobin (HbA1c)
Time frame: At baseline and at one-year follow-up
Blood test, expressed as %
Dietary habits
Time frame: At baseline and at one-year follow-up
Frequency of intake per month of fruits, vegetables, whole grains, lean proteins, saturated fats and added sugars, using the Canadian Food Intake Screener.
Smoking habits
Time frame: At baseline and at one-year follow-up
Self-reported smoking habits as current smoker, former smoker or never smoked, as well as frequency of smoking
Framingham risk score
Time frame: At baseline and at one-year follow-up
Estimated 10-year cardiovascular risk, expressed as a percentage (%)
1 secondary outcome
Participant feedback on intervention
Time frame: At baseline and at one-year follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- Background: PubMed 37650501Lajeunesse-Trempe F, Boit MK, Kaduka LU, De Lucia-Rolfe E, Baass A, Paquette M, Piche ME, Tchernof A, Christensen DL. Validation of the Fatty Liver Index for identifying non-alcoholic fatty liver disease in a Kenyan population. Trop Med Int Health. 2023 Oct;28(10):830-838. doi: 10.1111/tmi.13927. Epub 2023 Aug 31.
- Background: PubMed 39216457Leveille N, Provost H, Keutcha Kamani C, Chen M, Deghan Manshadi S, Ades M, Shanahan K, Nauche B, Drudi LM. Exploring Prognostic Implications of Race and Ethnicity in Patients With Peripheral Arterial Disease. J Surg Res. 2024 Oct;302:739-754. doi: 10.1016/j.jss.2024.07.120. Epub 2024 Aug 30.
- Background: PubMed 39358160Lajeunesse-Trempe F, Piche ME, Kaduka L, Lopez Y Taylor JR, Sagastume RC. Moving from helicopter research to proximity research and capacity building. Trends Endocrinol Metab. 2025 Mar;36(3):193-195. doi: 10.1016/j.tem.2024.08.011. Epub 2024 Oct 1.
- Background: PubMed 31023435Lane-Cordova AD, Khan SS, Grobman WA, Greenland P, Shah SJ. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Apr 30;73(16):2106-2116. doi: 10.1016/j.jacc.2018.12.092.
- Background: PubMed 33882682Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
- Background: PubMed 32063119Norris CM, Yip CYY, Nerenberg KA, Clavel MA, Pacheco C, Foulds HJA, Hardy M, Gonsalves CA, Jaffer S, Parry M, Colella TJF, Dhukai A, Grewal J, Price JAD, Levinsson ALE, Hart D, Harvey PJ, Van Spall HGC, Sarfi H, Sedlak TL, Ahmed SB, Baer C, Coutinho T, Edwards JD, Green CR, Kirkham AA, Srivaratharajah K, Dumanski S, Keeping-Burke L, Lappa N, Reid RD, Robert H, Smith G, Martin-Rhee M, Mulvagh SL. State of the Science in Women's Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender. J Am Heart Assoc. 2020 Feb 18;9(4):e015634. doi: 10.1161/JAHA.119.015634. Epub 2020 Feb 17. No abstract available.
- Background: PubMed 26321431Reading J. Confronting the Growing Crisis of Cardiovascular Disease and Heart Health Among Aboriginal Peoples in Canada. Can J Cardiol. 2015 Sep;31(9):1077-80. doi: 10.1016/j.cjca.2015.06.012. Epub 2015 Jun 21.
- Background: PubMed 32437302Piche ME, Tchernof A, Despres JP. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. Circ Res. 2020 May 22;126(11):1477-1500. doi: 10.1161/CIRCRESAHA.120.316101. Epub 2020 May 21.
- Background: PubMed 35718241Aziz H, Marchand M, Pop C, King A, Anand SS, Arbour L, Atzema C, Spaziano M, Merveille N, Filimon S, Poirier P, Huynh T. A Call to Action: Optimizing Indigenous Cardiovascular Health in Canada. Can J Cardiol. 2022 Oct;38(10):1584-1587. doi: 10.1016/j.cjca.2022.06.011. Epub 2022 Jun 16. No abstract available.
- Background: PubMed 38474854Lajeunesse-Trempe F, Piche ME, Poirier P, Tchernof A, Ayotte P. Adiposity Phenotypes and Associated Cardiometabolic Risk Profile in the Inuit Population of Nunavik. Nutrients. 2024 Mar 2;16(5):725. doi: 10.3390/nu16050725.
- Background: PubMed 31868600Anand SS, Abonyi S, Arbour L, Balasubramanian K, Brook J, Castleden H, Chrisjohn V, Cornelius I, Davis AD, Desai D, de Souza RJ, Friedrich MG, Harris S, Irvine J, L'Hommecourt J, Littlechild R, Mayotte L, McIntosh S, Morrison J, Oster RT, Picard M; Pictou Landing First Nation; Poirier P, Schulze KM, Toth EL; Canadian Alliance for Healthy Hearts and Minds First Nations Research Group. Explaining the variability in cardiovascular risk factors among First Nations communities in Canada: a population-based study. Lancet Planet Health. 2019 Dec;3(12):e511-e520. doi: 10.1016/S2542-5196(19)30237-2.
- Individual participant dataSharing planned: Undecided. According to OCAP(TM) principles, each community owns their data, controls its dissemination, and decides when and what research is in the best interests of their specific community.
Related trials for Cardiovascular (CV) Risk
Not yet recruiting
Effect of a Web-based Application With Integrated AI Chat for Cardiovascular Risk Support
AI Chatbot, Cardiovascular (CV) Risk
Enrolling by invitationObservational study
Real-World Validation of A Minimally Disruptive Ambulatory Blood Pressure Monitoring (ABPM) Huawei Smartwatch in Malaysia
Hypertension, Vascular Disease
Enrolling by invitationObservational study
Real-World Validation of A Huawei Smartwatch for Hypertension Risk Screening in Malaysia
Hypertension, Vascular Disease Risk
Not yet recruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Obesity, Overweight
Active, not recruiting
Italian Digital Primary Cardiovascular Prevention Study
Healthy Population
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cardiovascular risk screening and Follow-up of cardiovascular risk factors in people with Cardiovascular (CV) Risk and Metabolic Health, run by Laval University at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Coordinator (1-418-656-8711, santeinclusive@criucpq.ulaval.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Height in meters (time frame: Once, at baseline.). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07869069, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.